Search Results - "Manzari, Mandana T."

Fragment-based drug nanoaggregation reveals drivers of self-assembly by Chen, Chen, Wu, You, Wang, Shih-Ting, Berisha, Naxhije, Manzari, Mandana T., Vogt, Kristen, Gang, Oleg, Heller, Daniel A.

“…Drug nanoaggregates are particles that can deleteriously cause false positive results during drug screening efforts, but alternatively, they may be used to…”
Get full text

Targeted drug delivery strategies for precision medicines by Manzari, Mandana T., Shamay, Yosi, Kiguchi, Hiroto, Rosen, Neal, Scaltriti, Maurizio, Heller, Daniel A.

Get full text

Targeted drug delivery strategies for precision medicines by Manzari, Mandana T., Shamay, Yosi, Kiguchi, Hiroto, Rosen, Neal, Scaltriti, Maurizio, Heller, Daniel A.

“…Progress in the field of precision medicine has changed the landscape of cancer therapy. Precision medicine is propelled by technologies that enable molecular…”
Get full text

Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition by Bala Tannan, Neeta, Manzari, Mandana T., Herviou, Laurie, Da Silva Ferreira, Mariana, Hagen, Connor, Kiguchi, Hiroto, Manova-Todorova, Katia, Seshan, Venkatraman, de Stanchina, Elisa, Heller, Daniel A., Younes, Anas

“…Cancer and normal cells use multiple antiapoptotic BCL2 proteins to prevent cell death. Therapeutic targeting of multiple BCL2 family proteins enhances tumor…”
Get full text

Triepitopic Antibody Fusions Inhibit Cetuximab-Resistant BRAF and KRAS Mutant Tumors via EGFR Signal Repression by Spangler, Jamie B., Manzari, Mandana T., Rosalia, Elizabeth K., Chen, Tiffany F., Wittrup, K. Dane

“…Dysregulation of epidermal growth factor receptor (EGFR) is a hallmark of many epithelial cancers, rendering this receptor an attractive target for cancer…”
Get full text

Genomically informed small-molecule drugs overcome resistance to a sustained-release formulation of an engineered death receptor agonist in patient-derived tumor models by Manzari, Mandana T, Anderson, Gray R, Lin, Kevin H, Soderquist, Ryan S, Çakir, Merve, Zhang, Mitchell, Moore, Chandler E, Skelton, Rachel N, Fèvre, Maréva, Li, Xinghai, Bellucci, Joseph J, Wardell, Suzanne E, Costa, Simone A, Wood, Kris C, Chilkoti, Ashutosh

“…Extrinsic pathway agonists have failed repeatedly in the clinic for three core reasons: Inefficient ligand-induced receptor multimerization, poor…”
Get full text

Abstract LB-274: Overcoming colorectal cancer resistance to death receptor agonists: Design and delivery of treatment combinations by Manzari, Mandana T., Li, Xinghai, Anderson, Grace, Wood, Kris, Chilkoti, Ashutosh

“…Death Receptor 5 (DR5) is a key upregulated marker in colorectal cancer (CRC), overexpressed in over 90% of patients. There is a dire clinical need for drugs…”
Get full text